ReproCELL Incorporated [4978.T]
TOKYO, Apr 02 (Pulse News Wire) – ReproCELL Incorporated (4978.T) announced today that its project “Development of New GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors” was selected again for funding under theAMED’s public solicitation program “Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy” for fiscal year 2026. The grant covers the period from April 01, 2026, to March 31, 2027, with an estimated amount of ¥59.9 million.
The final amount and timing of disbursement will be confirmed upon receipt of notification from AMED. Formal confirmation of the grant amount is expected next year, and ReproCELL will promptly announce it once finalized.
However, the company stated that this selection will not impact its consolidated results for the fiscal year ending March 31, 2027.
🟢 Confidence: High AI-translated content.